Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01987310
Other study ID # SHEBA-13-0694-ZBE-CTIL
Secondary ID
Status Withdrawn
Phase N/A
First received October 27, 2013
Last updated April 25, 2017
Start date December 2015
Est. completion date December 2015

Study information

Verified date April 2017
Source Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the current study is to evaluate the association of fatty liver severity and endothelial function in Non-Alcoholic Fatty Liver Disease (NAFLD) patients and to find the impact of statin treatment compared to usual care or life style modification on endothelial function, liver steatosis and fibrosis.


Description:

The study cohort will include 150 patients with fatty liver per ultrasound or histology. The patients will be divided randomly to one of three arms: follow up group, lifestyle modification group, and statins therapy (Atorvastatin 20mg/d for 6 months). at screening, after 6 months (end of treatment), and 12 months the patients will undergo:

1. complete physical examination

2. blood pressure measurement

3. assessment of height and weight, body mass index and waist circumference

4. blood samples for complete blood count, fasting plasma glucose, fasting plasma insulin, lipid profile, liver enzymes, albumin, bilirubin, Prothrombin time (PT INR), Hemoglobin A1c, ferritin, adiponectin, C-reactive protein, Tumor necrosis factor alpha, Lipoprotein-phospholipase A2, Apolipoproteins B100, A1, C3, C4, ceruloplasmin

5. Liver elastography and sonographic liver fat quantification

6. Brachial artery flow-mediated dilatation (FMD) measurement


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- subjects willing to comply with study requirements and have signed an informed consent form

- fatty liver per abdominal ultrasound or liver biopsy

Exclusion Criteria:

- alcohol drinking >140g/week

- presence of hepatitis B or C or HIV

- known liver disease other than fatty liver

- usage of drugs known to cause liver steatosis

- subjects with known allergies or hypersensitivity to statins

- subjects with known cardiovascular/cerebrovascular disease

- subjects with known dyslipidemia requiring drug treatment

- subjects with diabetes mellitus

- history of drug or alcohol abuse

- refusal to sig the informed consent form

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
atorvastatin
atorvastatin 20 mg per day for 6 months
Behavioral:
lifestyle counseling
lifestyle modification by dietician counseling and follow up

Locations

Country Name City State
Israel Sheba Medical Center Ramat Gan

Sponsors (1)

Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in liver steatosis at 6 months Impact of statin treatment(which will be given for 6 months) compared to no intervention or lifestyle modification on liver steatosis and fibrosis. Liver steatosis will be assessed by sonographic liver fat quantification (hepatorenal sonographic index. baseline, 6 months and 12 months
Primary change from baseline in liver fibrosis at 6 months Impact of statin treatment(which will be given for 6 months) compared to no intervention or lifestyle modification on liver fibrosis. Liver fibrosis will be assessed by Real-Time shear wave elastography. baseline, 6 months and 12 months
Secondary endothelial function in Non-Alcoholic Fatty Liver Disease (NAFLD) patients measurement of endothelial function in NAFLD patients and finding the correlation between the degree of endothelial dysfunction and the severity of fatty liver disease. Endothelial function will be assessed by brachial artery flow-mediated (FMD) measurement at diagnosis and after 6 and 12 months. The severity of fatty liver disease will be assessed by liver elastography and sonographic liver fat quantification 12 months
Secondary relationship between blood parameters and liver steatosis and fibrosis levels of liver enzymes, liver synthetic function, blood lipids, insulin resistance, ferritin, adiponectin, C reactive protein, Tumor necrosis factor alpha and ceruloplasmin and their correlation with liver steatosis and fibrosis 12 months
Secondary relationship between blood parameters and endothelial function levels of liver enzymes, liver synthetic function, blood lipids, insulin resistance, ferritin, adiponectin, C reactive protein, tumor necrosis factor alpha and ceruloplasmin and their correlation with endothelial function at diagnosis and after 6 months and 12 months
Secondary change from baseline in endothelial function at 6 months Impact of statin treatment(which will be given for 6 months) compared to no intervention or lifestyle modification on endothelial function. Endothelial function will be assessed by flow mediated dilatation (FMD) of brachial artery. at diagnosis 6 months and 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT01277237 - The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease Phase 3
Active, not recruiting NCT04442620 - Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity N/A
Completed NCT01999101 - Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Phase 2
Completed NCT01327443 - Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease N/A
Active, not recruiting NCT01482065 - The Sleep, Liver Evaluation and Effective Pressure Study N/A
Completed NCT03135873 - Mastiha Treatment for Obese With NAFLD Diagnosis N/A
Completed NCT02686476 - Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes N/A
Completed NCT02820285 - Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH N/A
Completed NCT01556113 - Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease N/A
Recruiting NCT06080386 - UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
Terminated NCT02134522 - The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease N/A
Completed NCT01553500 - Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT05426382 - A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease N/A
Completed NCT03300661 - Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine N/A
Not yet recruiting NCT02178839 - The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease N/A
Recruiting NCT02038387 - Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD) N/A
Completed NCT01634048 - The Effect of Protein-enriched Diet on Body Composition and Appetite N/A
Completed NCT01874249 - Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease N/A
Completed NCT01966627 - Genetics of Fatty Liver Disease in Children N/A